Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by SRA Prescribers (US)

Analysis of: Health-Care Outlays Climb at Slowest Rate in Years (online.wsj.com)
"The data, which tally both private and public health spending, hardly represent a reprieve from soaring medical costs. Health-care spending again expanded faster than the overall economy, suggesting its share of GDP will climb as the economy remains mired in a protracted recession. In 2007, health...
Analysis of: Merck Serono: Study Published In JCO Shows Erbitux Enhances Efficacy In MCRC Patients With KRAS Wild-Type Tumors In 1st-Line Setting (www.medicalnewstoday.com)
Ebitux plus chemo is better than chemo alone in patients WITHOUT K-RAS mutations. Yes, but...
Analysis of: Response Genetics, Inc. Signs Amendment to Its Master Service Agreement With GlaxoSmithKline (GSK) as Preferred Provider of Genetic Testing Services (www.devicespace.com)
Response Genetics, Inc. Signs Amendment to Its Master Service Agreement With GlaxoSmithKline (GSK) as Preferred Provider of Genetic Testing Services. The sub-text is that GSK is preparing to "package" their targeted drugs with tests to identify the target! 
Analysis of: Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336 (jco.ascopubs.org)
The long and the short?? No evidenceof efficacy
Analysis of: FDA Approves Gleevec to Prevent Recurrence of Rare Gastrointestinal Cancer (www.therapeuticsdaily.com)
This valuable agent can now be used as an adjuvant (preventative) fashion in patients with gastrointestinal stroma tumors (GIST)
Analysis of: Bristol-Myers, Biotech Firm to Develop Cancer Drugs (online.wsj.com)
"Under the agreement, Bristol-Myers will pay Exelixis $195 million now and another $45 million in 2009 to codevelop the drugs, known as XL184 and XL281"
Analysis of: Blood-Cancer Drug Hits $1 Billion (online.wsj.com)
Despite my initial reservations Re: too frequent administrations, this is a blockbuster that is not only effective but relatively non toxic.
Analysis of: British Balance Benefit vs. Cost of Latest Drugs (www.nytimes.com)
Britain is reticent to pay for Sutent which will prolong the patients life by months.....
Analysis of: Scrutiny Grows of Drug Trials Abroad (online.wsj.com)
This article pertains to quality, accrual and safety, but in addition....
Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Analysis of: Scientists recommend 'black box' for Avastin (www.fiercepharma.com)
In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 518

Analytics


Generated at 2009-01-09T13:00:20.343